Effect of exercise interventions on sarcopenic obesity in middle-aged and older adults: a comprehensive review

Exercise for Sarcopenic Obesity: A Comprehensive Review

Article information

J Korean Biol Nurs Sci. 2023;25(4):254-265

Publication date (electronic) : 2023 November 22

doi : https://doi.org/10.7586/jkbns.23.0018

College of Nursing, ShinHan University, Dongducheon, Korea

Corresponding author: Hye-Ryoung Kim College of Nursing, ShinHan University. 30 Beolmadeul-ro 40beon-gil, Dongducheon, Gyeonggi-do 11340, Korea Tel: +82-31-870-0477 Fax: +82-31-870-1719 E-mail: hrkim@shinhan.ac.kr

Received 2023 October 5; Revised 2023 November 15; Accepted 2023 November 16.

Abstract

Purpose

This study examined the definitions, diagnostic criteria, and measurements of sarcopenic obesity and identified effective exercise interventions that improve cardiometabolic outcomes in middle-aged and older adults, in whom the prevalence of sarcopenic obesity is increasing.

Methods

This comprehensive review followed the principles of literature search, data extraction, and review, as described in the PRISMA 2009 guidelines.

Results

The 11 articles included in this study presented different concepts of sarcopenic obesity. Exercise interventions for sarcopenic obesity varied in their effects. Resistance exercise improved muscle mass and physical function, while aerobic exercise primarily impacted obesity and cardiometabolic indicators. Combined exercise had mixed results across indicators.

Conclusion

This study addressed a pressing public health concern in the context of an aging population, acknowledged the unique challenges of sarcopenic obesity, and attempted to clarify definitions and assessment methods, while identifying effective exercise interventions to reduce cardiometabolic risk. Sarcopenic obesity is a multifaceted condition with varying definitions and diagnostic criteria. Its association with cardiometabolic risk underscores the need for comprehensive assessments considering both muscle and obesity indicators. While exercise interventions hold promise for managing sarcopenic obesity, further research is required to establish effective strategies.

Keywords: Sarcopenia; Obesity; Risk; Muscle, skeletal; Exercise

INTRODUCTION

Due to the improvement in nutrition and medical technology development, life expectancy has increased worldwide, and the proportion of the elderly population is also increasing. In South Korea, older adults over 65 comprise 15.7% of the total population in 2020. Moreover, the super-aged society will launch at 20.6% in 2025 [1]. The aging population leads to an increasing prevalence of chronic diseases and medical expenses [2].

These problems are related to the increased obesity rate. The obesity rate among the Korean population aged 60~69 and over 70 in 2019 was 37.3% and 34.3%, respectively [3]. In particular, obesity among older adults increases the risk of chronic diseases, such as hypertension, diabetes, dyslipidemia, and cardiovascular disease. These situations also increase medical expenses [4].

With age, body composition changes, such as muscle mass decreases and fat mass increases. The muscle mass decreases by 3%-6% every year after age 60 [5]. On the other hand, advanced age increases adipose tissue by 10% in men and 6% in women [6]. Muscle loss and increased fat characterize obesity in older adults. This condition is called Sarcopenic obesity [7]. Unlike obesity in general, which is characterized by excess body fat and often results from an imbalance between calorie intake and expenditure, sarcopenic obesity combines obesity with muscle loss, increasing muscle weakness and vulnerability to falls, posing a dual challenge [7].

However, The definition of sarcopenic obesity is not clear. The criteria for sarcopenic obesity vary according to the purpose of a study, and the measurement of sarcopenic obesity is also not standardized. Despite the variety of criteria and different measurement methods, sarcopenic obesity means satisfying both sarcopenia and obesity criteria simultaneously. Baumgartner was the first to define Sarcopenic obesity as the concept of sarcopenia and obesity [8].

Although Baumgartner introduced the concept of sarcopenic obesity in 1998 [9], it is still not recognized as actual obesity due to decreased muscle mass despite increased fat mass, so its risk is overlooked and not adequately managed. Those who are average or underweight tend to be less concerned with sarcopenic obesity. However, even a normal weight or underweight state can not be free from sarcopenic obesity. In terms of phenotype, sarcopenic obesity may not look like being obese. So, It is likely not to consider a need for management. There is a requirement to improve the awareness of sarcopenic obesity.

According to a systematic review of definitions and diagnostic criteria [10], muscle mass or strength, such as walking speed and handgrip strength, can define sarcopenia. Moreover, BMI, fat mass, visceral fat area, and waist circumference are obesity indexes. Various ways measure these parameters. Specifically, muscle mass can be presented by total muscle mass or appendicular lean mass in a ratio of weight, squared height, or BMI. Other indicators for muscle mass are fat-free mass index by upper arm or thigh muscle circumference. Thus, The definition, diagnostic criteria, and measuring methods for sarcopenic obesity are in chaos.

The prevalence varies from 6.1% - 22.5% for men and 7.3% - 21.1% for women, depending on the diagnostic criteria of sarcopenic obesity [11-14]. However, the prevalence of sarcopenic obesity increases with physical inactivity due to long-term sedentary lifestyles, nutritional imbalance related to insufficient protein intake, systemic inflammatory disease, and age [7,15,16]. In sarcopenic obesity, muscle loss and body fat increment create a negative synergistic effect, increasing the cardiometabolic risk such as diabetes, hypertension, and dyslipidemia [17]. Moreover, Sarcopenic obesity causes physical dysfunctions such as falls and gait disorders in daily life and consequently lowers the quality of life of older adults [18].

To manage obesity in general, limit calories and exercise to lose weight. However, with general obesity management for sarcopenic obesity, the loss of muscle mass may worsen. Therefore, it is necessary to apply an intervention to manage sarcopenic obesity differentiated from general obesity management. The need for obesity management through exercise and diet is highly recognized, and many studies have been conducted. However, the awareness and management of sarcopenic obesity are poor. Because of unstandardized definitions, diagnostic criteria, and measuring methods, the management intervention for sarcopenic obesity is unclear. Therefore, reaching a consensus on a definition, diagnostic criteria, and measurement is necessary to identify effective exercise methods for sarcopenic obesity discriminated from general obesity management.

This study aims to identify the effective exercise interventions improving cardiometabolic outcomes of sarcopenic obesity for middle-aged and older adults with an increasing prevalence through a comprehensive literature review. The study will examine the definitions, diagnostic criteria, and measurement of sarcopenic obesity and outcome variables to test interventions' effectiveness.

METHODS

This comprehensive review followed the principles of literature search, data extraction, and review of the PRISMA 2009 guidelines [19]. This comprehensive review conducted the study selection process rigorously and methodically. The selection criteria were established a priori to ensure the relevance of the chosen studies to the research question. This process included a comprehensive database search and a meticulous examination of titles, abstracts, and full texts to determine whether each study met the predefined inclusion and exclusion criteria. Furthermore, the methodology for study selection was informed by consultations with another experienced researcher to enhance the robustness of the selection process.

Eligibility criteria

Inclusion criteria were as follows: adults over middle-aged living in the community, sarcopenic obesity subjects, prescribed exercise interventions and physical activities related to the study (possibly dietary combined exercise interventions), and indicators that can confirm the effectiveness of interventions. Exclusion criteria were as follows: without full-text, subjects without sarcopenic obesity, unclear definition of sarcopenic obesity, proceeding analysis, letter opinions, a study without or inappropriate outcome variables, and a study reported in languages other than English or Korean.

Information sources and search strategy

The study performed a literature search for articles published until May 2020 in databases such as PubMed, Embase, and CINAHL. The study checked for the literature search. ("middle-aged" OR "older adult" OR "elderly" OR "aging") AND ("exercise" OR "training" OR "physical activity") AND ("sarcopenic obesity" OR ("sarcopenia" AND "obesity")) AND ("blood pressure" OR "glucose" OR "triglyceride" OR "cholesterol" OR "cardiometabolic" OR "cardiovascular" OR "weight" OR "waist circumference" OR "BMI" OR "muscle mass")

Study selection and data extraction

In May 2020, The study conducted the first literature search using search terms and strategies. One thousand forty-nine documents were searched, including PubMed 259, Embase 725, and CINAHL 65. Figure 1 presents the whole screening process of the study. There were 11 articles included in the study (Appendix 1).

Figure 1.

Flow diagram of study screening.

Quality assessment

This study adopted the Cochrane Collaboration Risk of Bias tool for quality assessment [20]. The risk of bias assessment process was also enhanced by soliciting consultation from a fellow researcher, ensuring a more comprehensive and rigorous evaluation. Two investigators evaluated independently using the Cochrane Collaboration Risk of Bias tool and confirmed together. Assessment criteria were random sequence generation, allocation concealment, blinding participants and personnel, blinding outcome assessment, incomplete outcome data, and selective reporting.

Table 1 presents the assessment results. This study analyzed all included articles irrespective of the risk of bias due to the relevant article shortage.

Table 1.

Assessment of the Risk of Bias of the Included Articles

RESULTS

Characteristics of participants and sarcopenic obesity

Out of eleven studies, eight were female participants, two were male participants, and one was male and female. The average age of participants was between 55 and 90 years old.

The studies use the indicators of sarcopenia and obesity to define sarcopenic obesity (Table 2). Various indicators were applied alone or in combination to define sarcopenia. Even though its calculation methods and diagnostic criteria differed, the skeletal muscle index (SMI) was the most prevalent sarcopenic indicator (6 studies). Obesity indicators were body mass index (BMI), body fat mass, and visceral fat area alone or in combination. Body fat mass (7 studies) was the most prevalent indicator, followed by BMI (5 studies). The body composition was measured by bioelectrical impedance analysis (6 studies) or dual-energy X-ray absorptiometry (5 studies).

Table 2.

Summary of the Included Articles

Outcome variables

Outcome variables for intervention were muscle indicators, obesity indicators, physical function indicators, and cardiometabolic indicators (Table 3).

Table 3.

Effects of Exercise on Muscle, Obesity, and Physical Function Indicators

Lean mass (kg) and SMI (%) were prevalent as muscle indicators. Twenty-one muscle indicators were evaluated in ten studies (90.9%), of which nine (42.9%) showed significant changes. Most studies adopted BMI (kg/m2) or Body fat of total body or appendicular in percentage (%) or kilogram (kg) as obesity indicators. In the obesity indicator, there were significant changes in 16 out of 37 (43.2%) variables in eleven (100%) studies. Physical functions were categorized as speed, balance, flexibility, strength, etc. A walk test was the most prevalent for speed evaluation, followed by a rising test. Eight studies (72.7%) evaluated thirty-one physical function indicators, and eighteen (58.1%) showed significant results.

Six (54.5%) of the eleven studies evaluated cardiometabolic indicators such as blood pressure, serum glucose, cholesterol, an inflammatory cytokine, artery thickness, and blood flow velocity (Table 4). Of the forty-eight cardiometabolic indicators evaluated, sixteen showed significant results.

Table 4.

Effects of Exercise on Cardiometabolic Indicators

The Exercises and effects

Aerobic exercise

There was only one study that applied aerobic exercise. The study applied moderate- and vigorous-intensity exercise once a week for three weeks, and the session lasted one hour (Table 2). Among the obesity indicators, body weight, BMI, and body fat decreased. However, no significant changes in the muscle indicators and physical function were not evaluated (Table 3). Cardiometabolic indicators had improved in all measured variables, such as total cholesterol, triglyceride, low-density lipoprotein cholesterol, and systolic blood pressure, except for high-density lipoprotein cholesterol (Table 4).

Resistance exercise

Five out of eight studies applied moderate- and vigorous-intensity exercises. The other three studies applied moderate-intensity exercises. The minimum 35-minute to maximum one-hour exercise was performed twice or thrice a week for 12 to 16 weeks (Table 2).

In muscle indicators, appendicular lean mass or appendicular lean mass index increased in four out of eight resistance exercise studies. Still, there were no significant changes in all three studies evaluating skeletal muscle or SMI (Table 3). For the obesity indicator, six out of eight studies investigated a body fat percentage and reported a decrease in four of them. One study reported decreased waist circumference or waist-to-hip ratio. On the other hand, three and five studies measured body weight and BMI, respectively, but showed no significant changes (Table 3).

Six out of eight studies evaluated physical function indicators. Speed improved in four out of six studies. The study that evaluated the balance was three out of eight studies, and all three studies reported improvement. The strength was evaluated in four out of eight studies. One out of four studies reported enhanced handgrip strength. On the other hand, one study reported increased knee extension (Table 3).

Three out of eight studies evaluated cardiometabolic indicators. However, only one out of three studies reported improved cardiometabolic risks such as glucose, triglyceride, high-density lipoprotein cholesterol, High-sensitivity c-reactive protein, and Interleukin-6 (Table 4).

Combination exercise

Two studies adopted moderate- and vigorous-intensity combination exercise (Table 2). One study applied the 50- to 80-minute exercise five days per week for 24 weeks, and the other applied one-hour exercise twice weekly for twelve weeks.

The appendicular muscle mass as muscle indicators increased in one study. However, there were no significant changes in SMI (Table 3). For the obesity indicator, two studies all reported decreased body fat percentage. In addition, one out of two studies reported a decrease in total fat mass, trunk fat mass, and appendicular fat mass. On the other hand, only one study evaluated waist circumference, and no significant changes (Table 3).

Two studies evaluated physical function indicators. However, speed showed improvement in one study evaluated through the walk test. Enhanced strength was reported in both studies through the knee extension test and handgrip strength test, respectively (Table 3).

Only one out of two studies that evaluated cardiometabolic indicators reported improved systolic blood pressure, total cholesterol, carotid artery intima-media thickness, peak systolic flow velocity, end-diastolic flow velocity, and wall shear rate (Table 4).

DISCUSSION

This study investigated the definitions, diagnostic criteria, and measurement of sarcopenic obesity and the effective exercise interventions improving cardiometabolic outcomes of sarcopenic obesity for adults over middle-aged. Unfortunately, there were few attempts to manage sarcopenic obesity by relating it to cardiometabolic risk, and only eleven studies met the criteria. Identifying eleven articles in this study, concepts of sarcopenic obesity were different. Even though the same indicators were used to define sarcopenic obesity, it was difficult to compare the study results because the measurement methods and units were not the same. In addition, the cutoff values were all different.

Sarcopenic obesity, in which muscle loss and fat increase simultaneously, has various pathophysiological changes. Decreased skeletal muscle mass increases fragility and loss of independence associated with decreased muscle strength, impairing its role as an endocrine organ. As an endocrine organ, skeletal muscle release various myokines such as adiponectin, apelin, β‐aminoisobutyric acid, fibroblast growth factor 21, Interleukin-6, Interleukin‐10, Interleukin-15, irisin, myonectin, and musclin [9]. These myokines are involved in the metabolism of glucose, fat, inflammation, and cardiometabolic risk. Moreover, excessive proinflammatory cytokines from exacerbated adipose tissue alter adipokine expressions, which creates a high flow of lipids to muscle fibers [9,21]. The atrophy of skeletal muscle cells decreases the expression of glucose transporter type 4 in muscle fibers and reduces the demand for insulin-dependent glucose uptake [22]. The proinflammatory state and lipid accumulation in muscle fibers, on the other hand, induce the activity of intracellular kinases that phosphorylate and inactivate the insulin receptor and substrates [9]. Insulin resistance is a central mechanism for associating sarcopenic obesity with cardiovascular disease [21]. As such, sarcopenic obesity acts as a risk factor for cardiovascular disease. Therefore, to define sarcopenic obesity, it is necessary to consider cardiometabolic risk as well as muscle and obesity indicators. However, as can be seen from the results of this review, only six out of eleven studies (approximately 54.5%) adopted cardiometabolic indicators. In the case of studies employing resistance exercise, only one study considered cardiometabolic indicators.

Moreover, the application of exercise intervention for sarcopenic obesity should evaluate the increase in skeletal muscle and decrease in body fat based on the definition of sarcopenic obesity. However, while the decrease in body fat was assessed in ten studies, only four out of eleven studies evaluated the skeletal muscle mass or skeletal muscle mass index, and none showed significant results in increasing skeletal muscle. These results raise doubts about the suitability of intervention for sarcopenic obesity. Therefore, awareness of this still needs to be improved, and more research is necessary to establish diagnostic criteria for cardiometabolic risk for sarcopenic obesity.

So far, bioelectrical impedance analysis and dual-energy X-ray absorptiometry have been the most prevalent methods to measure muscle mass or body fat. However, it is also necessary to consider the ease of screening, such as tape measure. Calf or thigh circumference might be an alternative to muscle mass measurement [23-26]. Moreover, waist circumference is a good indicator of central obesity in the ratio of the hip circumference or height [27]. In particular, the waist to hip ratio or the waist to height ratio are indicators that can quickly identify the cardiometabolic risk caused by the problem of body fat distribution, which is easy to overlook in normal BMI [27-29]. Calf circumference is associated with cardiovascular risk factors, particularly insulin resistance and carotid atherosclerosis [30]. Calf circumference cutoff values for sarcopenia vary according to age, gender, and race. For Koreans over 70, the calf circumference cutoff was < 35 cm for men and < 33 cm for women [23]. For Japanese over 40 years old and Brazil over 60, the calf circumference cutoff was < 34 cm for men and < 33 cm [24,25]. In Indonesia, over 60 years of age, the calf circumference cutoff was male < 34 cm and female < 29 cm [26]. Also, a smaller thigh circumference is associated with increased cardiovascular and coronary heart disease and hypertension [31,32]. In American subjects 18 years of age or older, an increase in thigh circumference by 1 cm resulted in a 6% decrease in cardiovascular mortality [33]. Thus, these anthropometric indices enable early detection of sarcopenic obesity, including cardiometabolic risk. If thigh, calf circumference, and waist circumference in ratio to hip or height are managed together in daily life, it would be possible to prevent cardiovascular disease, significantly reducing medical expenses.

Even though there were exercise interventions for sarcopenic obesity, such as aerobic, resistance, and combination exercise, there were too few studies to compare the impact of the outcome variable in sarcopenic obesity subjects. However, Aerobic exercise effectively manages cardiometabolic risk by improving glycemic control, cardiorespiratory fitness, myocardial function, vascular endothelial function, visceral adiposity, inflammation, and dyslipidemia [34]. On the other hand, resistance exercise increases muscle mass by stimulating the entire muscle and muscle fiber hypertrophy [35]. In a weight loss program for older adults, combined aerobic and resistance exercise improved the participants' functional status while preserving lean mass [36]. Combination exercise benefits weight loss, fat loss, cardiovascular health, leptin levels, and aerobic capacity [37]. Thus, combination exercise may help improve body composition and cardiometabolic risks in obese older people, ultimately improving cardiovascular function and health [38].

Exercise interventions for sarcopenic obese subjects should reduce body fat through aerobic exercise and increase muscle mass and strength through resistance exercise to create a synergistic effect, consequently reducing cardiometabolic risk. In particular, improving lower extremity muscle health may help prevent and ameliorate sarcopenic obesity while lowering the risk associated with metabolic syndrome and premature death and may reduce certain lipid levels, particularly those related to the development of cardiovascular disease [22,39]. However, additional research should investigate which aerobic and resistance exercise ratio in combination exercise is an effective intervention for sarcopenic obesity

Also, considering exercise intensity and frequency would be necessary. Considering the age at which sarcopenic obesity is prevalent, it is necessary to consider practical exercise applications that can be adopted continuously without being excessive. In this review, There were significant changes in muscle, obesity, and physical function indicators in studies that applied moderate-intensity exercise. However, no significant changes were observed in cardiometabolic indicators, and even more were not evaluated. Additional research is needed.

This study has some limitations. This study tried to find out exercise intervention effects on sarcopenic obesity. However, there were few preliminary studies. Because of the relevant article shortage, this study included articles irrespective of the risk of bias. Moreover, some study results are not limited to exercise, including diet interventions. In addition, the limitation of restricting the search to English-language databases resulted in a narrow scope by excluding publications in languages other than English.

For this reason, it was difficult to verify the effect of pure exercise intervention. Therefore, it is necessary to be careful in interpreting the results. Nevertheless, this study may raise awareness of sarcopenic obesity and its management, seeking to clarify definitions and assessing methods while identifying exercise interventions to improve the cardiometabolic risks. Further research on management and its effect on sarcopenic obesity is needed.

CONCLUSION

This study addresses a pressing public health concern in the context of an aging population, acknowledges the unique challenges of sarcopenic obesity, and tries to clarify definitions and assessment methods while identifying effective exercise interventions to improve the cardiometabolic risks. Sarcopenic obesity is a multifaceted condition with varying definitions and diagnostic criteria. Its association with cardiometabolic risk underscores the need for comprehensive assessments considering both muscle and obesity indicators. While exercise interventions hold promise for managing sarcopenic obesity, further research is required to establish effective strategies.

Notes

CONFLICT OF INTEREST

The author declared that no conflict of interest.

AUTHORSHIP

HRK contributed to the conception and design of this study; HRK collected data; HRK performed the statistical analysis and interpretation; HRK drafted the manuscript; HRK critically revised the manuscript; HRK supervised the whole study process. The authors read and approved the final manuscript.

FUNDING

None.

DATA AVAILABILITY

The data supporting the findings of this study are available in the article and appendix.

References

1. Statistics Korea. 2020 Statistics on the Aged [Internet]. Seoul: Statistics Korea; 2020 [2023 Sep 28]. Available from: https://kostat.go.kr/board.es?mid=a20111030000&bid=11759&act=view&list_no=388599.

2. Nam GE, Kim YH, Han K, Jung JH, Rhee EJ, Lee SS, et al. Obesity fact sheet in Korea, 2019: prevalence of obesity and abdominal obesity from 2009 to 2018 and social factors. Journal of Obesity and Metabolic Syndrom 2020;29(2):124–132. http://doi.org/10.7570/jomes20058.

3. Welfare KMoHa. National Health Statistics - The eighth Korea National Health and Nutrition Examination Survey (KNHAES VI-1) 2019 Agency DCaP; 2021.

4. Hyun KR, Kang S, Lee S. Population aging and healthcare expenditure in Korea. Health Economics 2016;25(10):1239–1251. http://doi.org/10.1002/hec.3209.

5. Dipietro L, Dziura J. Exercise: a prescription to delay the effects of aging. The Physician and Sportsmedicine 2000;28(10):77–78. http://doi.org/10.3810/psm.2000.10.1253.

6. Ponti F, Santoro A, Mercatelli D, Gasperini C, Conte M, Martucci M, et al. Aging and imaging assessment of body composition: from fat to facts. Frontiers in Endocrinology 2020;10(861)http://doi.org/10.3389/fendo.2019.00861.

7. Koliaki C, Liatis S, Dalamaga M, Kokkinos A. Sarcopenic obesity: epidemiologic evidence, pathophysiology, and therapeutic perspectives. Current Obesity Reports 2019;8(4):458–471. http://doi.org/10.1007/s13679-019-00359-9.

8. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. American Journal of Epidemiology 1998;147(8):755–763. http://doi.org/10.1093/oxfordjournals.aje.a009520.

9. Chen W, Wang L, You W, Shan T. Myokines mediate the cross talk between skeletal muscle and other organs. Journal of Cellular Physiology 2021;236(4):2393–2412. http://doi.org/10.1002/jcp.30033.

10. Donini LM, Busetto L, Bauer JM, Bischoff S, Boirie Y, Cederholm T, et al. Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. Clinical Nutrition 2020;39(8):2368–2388. http://doi.org/10.1016/j.clnu.2019.11.024.

11. Hwang B, Lim JY, Lee J, Choi NK, Ahn YO, Park BJ. Prevalence rate and associated factors of sarcopenic obesity in korean elderly population. Journal of Korean Medical Science 2012;27(7):748–755. http://doi.org/10.3346/jkms.2012.27.7.748.

12. Perna S, Peroni G, Faliva MA, Bartolo A, Naso M, Miccono A, et al. Sarcopenia and sarcopenic obesity in comparison: prevalence, metabolic profile, and key differences. A cross-sectional study in Italian hospitalized elderly. Aging Clinical and Experimental Research 2017;29(6):1249–1258. http://doi.org/10.1007/s40520-016-0701-8.

13. Öztürk ZA, Türkbeyler İH, Abiyev A, Kul S, Edizer B, Yakaryılmaz FD, et al. Health-related quality of life and fall risk associated with age-related body composition changes; sarcopenia, obesity and sarcopenic obesity. Internal Medicine Journal 2018;48(8):973–981. http://doi.org/10.1111/imj.13935.

14. Atmis V, Yalcin A, Silay K, Ulutas S, Bahsi R, Turgut T, et al. The relationship between all-cause mortality sarcopenia and sarcopenic obesity among hospitalized older people. Aging Clinical and Experimental Research 2019;31(11):1563–1572. http://doi.org/10.1007/s40520-019-01277-5.

15. Oh C, Jeon BH, Reid Storm SN, Jho S, No JK. The most effective factors to offset sarcopenia and obesity in the older Korean: physical activity, vitamin D, and protein intake. Nutrition 2017;33:169–173. http://doi.org/10.1016/j.nut.2016.06.004.

16. Coker RH, Wolfe RR. Bedrest and sarcopenia. Current Opinion in Clinical Nutrition and Metabolic Care 2012;15(1):7–11. http://doi.org/10.1097/MCO.0b013e32834da629.

17. Rolland Y, Czerwinski S, Kan G, Morley J, Cesari M, Onder G, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. The Journal of Nutrition Health and Aging 2008;12:433–450. http://doi.org/10.1007/BF02982704.

18. Janssen I, Heymsfield S, Ross R. Low relative skeletal muscle mass is associated with functional impairment and physical disability. Journal of the American Geriatrics Society 2002;50:889–896. http://doi.org/10.1046/j.1532-5415.2002.50216.x.

19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7)e1000097. http://doi.org/10.1371/journal.pmed.1000097.

20. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. http://doi.org/10.1136/bmj.d5928.

21. Hong SH, Choi KM. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences. International Journal of Molecular Sciences 2020;21(2)http://doi.org/10.3390/ijms21020494.

22. Hamasaki H, Kawashima Y, Adachi H, Moriyama S, Katsuyama H, Sako A, et al. Associations between lower extremity muscle mass and metabolic parameters related to obesity in Japanese obese patients with type 2 diabetes. PeerJ 2015;3e942. http://doi.org/10.7717/peerj.942.

23. Kim S, Kim M, Lee Y, Kim B, Yoon TY, Won CW. Calf circumference as a simple screening marker for diagnosing sarcopenia in older Korean adults: the Korean frailty and aging cohort study (KFACS). Journal of Korean Medical Science 2018;33(20)e151. http://doi.org/10.3346/jkms.2018.33.e151.

24. Kawakami R, Murakami H, Sanada K, Tanaka N, Sawada SS, Tabata I, et al. Calf circumference as a surrogate marker of muscle mass for diagnosing sarcopenia in Japanese men and women. Geriatrics & Gerontology International 2015;15(8):969–976. http://doi.org/10.1111/ggi.12377.

25. Pagotto V, Santos KFD, Malaquias SG, Bachion MM, Silveira EA. Calf circumference: clinical validation for evaluation of muscle mass in the elderly. Revista Brasileira de Enfermagem 2018;71(2):322–328. http://doi.org/10.1590/0034-7167-2017-0121.

26. Mienche M, Setiati S, Setyohadi B, Kurniawan J, Laksmi PW, Ariane A, et al. Diagnostic performance of calf circumference, thigh circumference, and SARC-F questionnaire to identify sarcopenia in elderly compared to Asian working group for sarcopenia's diagnostic standard. Acta Medica Indonesiana 2019;51(2):117–127.

27. Kim HR, Kim HS. Optimal cutoffs of cardiometabolic risk for postmenopausal Korean women. Asian Nursing Research 2017;11(2):107–112. http://doi.org/10.1016/j.anr.2017.05.003.

28. Lundblad MW, Jacobsen BK, Johansson J, Grimsgaard S, Andersen LF, Hopstock LA. Anthropometric measures are satisfactory substitutes for the DXA-derived visceral adipose tissue in the association with cardiometabolic risk-The Tromsø Study 2015-2016. Obesity Science and Practice 2021;7(5):525–534. http://doi.org/10.1002/osp4.517.

29. Cota BC, Ribeiro SAV, Priore SE, Juvanhol LL, de Faria ER, de Faria FR, et al. Anthropometric and body composition parameters in adolescents with the metabolically obese normal-weight phenotype. British Journal of Nutrition 2022;127(10):1458–1466. http://doi.org/10.1017/s0007114521002427.

30. Park JS, Cho MH, Ahn CW, Kim KR, Huh KB. The association of insulin resistance and carotid atherosclerosis with thigh and calf circumference in patients with type 2 diabetes. Cardiovascular Diabetology 2012;11:62. http://doi.org/10.1186/1475-2840-11-62.

31. Heitmann BL, Frederiksen P. Thigh circumference and risk of heart disease and premature death: prospective cohort study. BMJ 2009;339:b3292. http://doi.org/10.1136/bmj.b3292.

32. Shi J, Yang Z, Niu Y, Zhang W, Lin N, Li X, et al. Large thigh circumference is associated with lower blood pressure in overweight and obese individuals: a community-based study. Endocrine Connections 2020;9(4):271–278. http://doi.org/10.1530/ec-19-0539.

33. Chen CL, Liu L, Huang JY, Yu YL, Shen G, Lo K, et al. Thigh circumference and risk of all-cause, cardiovascular and cerebrovascular mortality: a cohort study. Risk Management and Healthcare Policy 2020;13:1977–1987. http://doi.org/10.2147/rmhp.S264435.

34. Miele EM, Headley SAE. The effects of chronic aerobic exercise on cardiovascular risk factors in persons with diabetes mellitus. Current Diabetes Reports 2017;17(10):97. http://doi.org/10.1007/s11892-017-0927-7.

35. Lavin KM, Roberts BM, Fry CS, Moro T, Rasmussen BB, Bamman MM. The importance of resistance exercise training to combat neuromuscular aging. Physiology 2019;34(2):112–122. http://doi.org/10.1152/physiol.00044.2018.

36. Villareal DT, Aguirre L, Gurney AB, Waters DL, Sinacore DR, Colombo E, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. The New England Journal of Medicine 2017;376(20):1943–1955. http://doi.org/10.1056/NEJMoa1616338.

37. Ho SS, Dhaliwal SS, Hills AP, Pal S. The effect of 12 weeks of aerobic, resistance or combination exercise training on cardiovascular risk factors in the overweight and obese in a randomized trial. BMC Public Health 2012;12:704. http://doi.org/10.1186/1471-2458-12-704.

38. Kim SW, Jung WS, Park W, Park HY. Twelve weeks of combined resistance and aerobic exercise improves cardiometabolic biomarkers and enhances red blood cell hemorheological function in obese older men: a randomized controlled trial. International Journal of Environmental Research and Public Health 2019;16(24)http://doi.org/10.3390/ijerph16245020.

39. Vella CA, Nelson MC, Unkart JT, Miljkovic I, Allison MA. Skeletal muscle area and density are associated with lipid and lipoprotein cholesterol levels: the multi-ethnic study of atherosclerosis. Journal of Clinical Lipidology 2020;14(1):143–153. http://doi.org/10.1016/j.jacl.2020.01.002.

Appendices

Appendix. List of reviewed articles for the study

A1. Barbat-Artigas S, Garnier S, Joffroy S, Riesco É, Sanguignol F, Vellas B, et al. Caloric restriction and aerobic exercise in sarcopenic and non-sarcopenic obese women: an observational and retrospective study. Journal of Cachexia, Sarcopenia and Muscle. 2016;7(3):284-289. http://doi.org/10.1002/jcsm.12075

A2. Nabuco HCG, Tomeleri CM, Fernandes RR, Sugihara Junior P, Cavalcante EF, Cunha PM, et al. Effect of whey protein supplementation combined with resistance training on body composition, muscular strength, functional capacity, and plasma-metabolism biomarkers in older women with sarcopenic obesity: a randomized, double-blind, placebo-controlled trial. Clinical Nutrition ESPEN. 2019;32:88-95. http://doi.org/10.1016/j.clnesp.2019.04.007

A3. Carvalho LP, Pion CH, Boutros GEH, Gaudreau P, Chevalier S, Bélanger M, et al. Effect of a 12-week mixed power training on physical function in dynapenic-obese older men: does severity of dynapenia matter? Aging Clinical and Experimental Research. 2019;31(7):977-984. http://doi.org/10.1007/s40520-018-1048-0

A4. Stoever K, Heber A, Eichberg S, Brixius K. Influences of resistance training on physical function in older, obese men and women with sarcopenia. Journal of Geriatric Physical Therapy. 2018;41(1):20-27. http://doi.org/10.1519/jpt.0000000000000105

A5. Liao CD, Tsauo JY, Huang SW, Ku JW, Hsiao DJ, Liou TH. Effects of elastic band exercise on lean mass and physical capacity in older women with sarcopenic obesity: a randomized controlled trial. Scientific Reports. 2018;8(1):2317. http://doi.org/10.1038/s41598-018-20677-7

A6. de Oliveira Silva A, Dutra MT, de Moraes W, Funghetto SS, Lopes de Farias D, Dos Santos PHF, et al. Resistance training-induced gains in muscle strength, body composition, and functional capacity are attenuated in elderly women with sarcopenic obesity. Clinical Intervention in Aging. 2018;13:411-417. http://doi.org/10.2147/cia.S156174

A7. Liao CD, Tsauo JY, Lin LF, Huang SW, Ku JW, Chou LC, et al. Effects of elastic resistance exercise on body composition and physical capacity in older women with sarcopenic obesity: a CONSORT-compliant prospective randomized controlled trial. Medicine. 2017;96(23):e7115. http://doi.org/10.1097/md.0000000000007115

A8. Huang SW, Ku JW, Lin LF, Liao CD, Chou LC, Liou TH. Body composition influenced by progressive elastic band resistance exercise of sarcopenic obesity elderly women: a pilot randomized controlled trial. European Journal of Physical and Rehabilitation Medicine. 2017;53(4):556-563. http://doi.org/10.23736/s1973-9087.17.04443-4

A9. Maltais ML, Perreault K, Courchesne-Loyer A, Lagacé JC, Barsalani R, Dionne IJ. Effect of resistance training and various sources of protein supplementation on body fat mass and metabolic profile in sarcopenic overweight older adult men: a pilot study. International Journal of Sport Nutrition and Exercise Metabolism. 2016;26(1):71-77. http://doi.org/10.1123/ijsnem.2015-0160

A10. Park J, Kwon Y, Park H. Effects of 24-week aerobic and resistance training on carotid artery intima-media thickness and flow velocity in elderly women with sarcopenic obesity. Journal of Atherosclerosis Thrombosis. 2017;24(11):1117-1124. http://doi.org/10.5551/jat.39065

A11. Kim H, Kim M, Kojima N, Fujino K, Hosoi E, Kobayashi H, et al. Exercise and nutritional supplementation on community-dwelling elderly Japanese women with sarcopenic obesity: a randomized controlled trial. Journal of the American Medical Directors Association. 2016;17(11):1011-1019. http://doi.org/10.1016/j.jamda.2016.06.016

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article ID	Author (yr)	Age (yr)	Gender	Exercise	Period (week)	Intervention frequency and intensity	Sarcopenia criteria	Obesity criteria	Assessment
A1	Barbat-Artigas et al. (2016)	50~60	Female	Aerobic	3	Cycle ergometer and walking, 1 hour, once a week (moderate & vigorous)	Lean BMI (kg/m²)	BMI ≥ 30 and BFM ≥ 40	BIA
A2	Nabuco et al. (2019)	> 60	Female	Resistance	16	Whole body program, thrice/week (moderate & vigorous)	Appendicular lean soft tissue < 15.02 kg	BFM ≥ 35	DXA
A3	Carvalho et al. (2019)	55~80	Male	Resistance	12	Mixed power training, thrice/week (moderate & vigorous)	Handgrip strength/Body weight	BFM ≥ 25	DXA
A4	Stoever et al. (2018)	> 65	Female, Male	Resistance	16	Progressive resistance training, 1 hour, twice a week (moderate & vigorous)	Female: SMI ≤ 27.6%, hand-grip strength ≤ 21 kg, SPPB score ≤ 8, 4-meter gait speed < 0.8 m/s	BMI ≥ 30	BIA
A4	Stoever et al. (2018)	> 65	Female, Male	Resistance	16		Male: SMI ≤ 37%, Hand-grip strength ≤ 32 kg, SPPB score ≤ 8, 4-meter gait speed < 0.8 m/s	BMI ≥ 30	BIA
A5	Liao et al. (2018)	60~80	Female	Resistance	12	Elastic band training, 35-40 min, thrice/week (moderate)	SMI (TSM/total body mass × 100) < 27.6%	BFM ≥ 30	BIA
A6	de Oliveira Silva et al. (2018)	> 60	Female	Resistance	16	Muscle resistance training, 40-50min, twice a week (moderate & vigorous)	Appendicular fat-free mass (measured – predicted^†) ≤ 3.4	BMI ≥ 27	DXA
A7	Liao et al. (2017)	60~80	Female	Resistance	12	Elastic band training, 35-40 min, thrice/week (moderate)	SMI (TSM/height²)<7.15 kg/m²	BFM ≥ 30	BIA
A8	Huang et al. (2017)	60~90	Female	Resistance	12	Elastic band training, 55 min, thrice/week (moderate)	SMI (TSM/total body mass × 100) < 27.6%	BFM ≥ 30	DXA
A9	Maltais et al. (2016)	60~75	Male	Resistance	16	Muscle resistance training, 1 hour, thrice/week (moderate & vigorous)	Appendicular lean mass index ≤ 10.75 kg/m²	BMI ≥ 30	DXA
A10	Park et al. (2017)	65~84	Female	Combination	24	Combined exercise program, 50-80 min, quintuple/week (moderate & vigorous)	SMI (ASM/weight) < 25.1%	BMI ≥ 25	BIA
A11	Kim et al. (2016)	> 70	Female	Combination	12	Chair exercise, band, rotated training machine, stationary bicycle, 1 hour, twice a week (moderate & vigorous)	SMI (ASM/height²) < 5.67 kg/m²	BFM ≥ 30	BIA

Indicator	Variable		Article ID
			AE	RE								CE
			A1	A2	A3	A4	A5	A6	A7	A8	A9	A10	A11
Muscle	Skeletal muscle mass (kg)						±			±
	Skeletal muscle mass index (%)					±	±			±			±
	Trunk muscle (kg)									▲
	Appendicular muscle mass (kg)									±			▲
	Lean mass (kg)		±		▲			±	±		▲
	Lean mass index (kg/m²)		±				±
	Appendicular lean mass (kg)			▲			▲		▲
	Appendicular lean mass index (kg/m²)						▲				▲
Obesity	Body weight (kg)		▼					±		±	±
	Body mass index (kg/m²)		▼		±	±		±		±	±
	Waist circumference (cm)			▼								±
	Hip circumference (cm)			±				±
	Waist-hip ratio			▼				±
	Neck circumference (cm)							±
	Body fat percentage (%)		▼	▼	±		▼	±	▼	▼		▼	▼
	Total fat mass (kg)			±	±				▼	▼	±		▼
	Trunk fat mass (kg)			±						±			▼
	Appendicular fat mass (kg)									±			▼
Physical function	Speed	Walk test (sec, m/sec, repetitions)		▼	±	±	▲		±			▲	±
		Stair test (n)			±		▲
		Rising test (sec, repetitions)		▼		▼	▼	▲	±			±
		Timed-up-and-go test (sec)			±		▲	▼	±
	Balance	Single leg stance (sec)							▲
		Functional reach distance (cm)					▲
		SPPB score				▲
	Flexibility	Sit and reach (cm)										±
	Strength	Knee extension (kg)		▲				`					▲
	Strength	Handgrip strength (kg)			▲	±			±			▲	±
	Other	Global physical capacity score					▲

Cardiometabolic indicator	Article ID
	AE	RE								CE
	A1	A2	A3	A4	A5	A6	A7	A8	A9	A10	A11
Systolic blood pressure (mmHg)	▼	±								▼	±
Diastolic blood pressure (mmHg)	±	±								±	±
Glucose (mg/dL or mmol/L)		▼							±
Insulin (mU/mL or pmol/L)		±							±
HbA1c (%)											±
Homeostasis model assessment-insulin resistance		±
Total cholesterol (mg/dL or mmol/L)	▼	±						±	±	▼	±
Triglycerides (mg/dL or mmol/L)	▼	▼						±	±	±	±
High-density lipoprotein cholesterol (mg/dL or mmol/L)	▼	▲						±	±	±
Low-density lipoprotein cholesterol (mg/dL or mmol/L)	▼	±						±	±	±
High-sensitivity c-reactive protein (mg/L or mmol/L)		▼						±	±	±	±
Interleukin-6 (pg/mL)		▼							±		±
Carotid artery intima-media thickness (mm)										▼
Peak systolic flow velocity (cm/sec)										▲
End diastolic flow velocity (cm/sec)										▲
Wall shear rate (sec)										▲

Article ID	Author (yr)	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)
A1	Barbat-Artigas et al. (2016)	Unclear	Unclear	Low	Unclear	Low	Low
A2	Nabuco et al. (2019)	Low	Low	Low	Low	Low	Low
A3	Carvalho et al. (2019)	Unclear	Unclear	Low	Unclear	Unclear	Low
A4	Stoever et al. (2018)	Unclear	Unclear	Low	High	Low	Low
A5	Liao et al. (2018)	Low	Low	Low	High	Low	Low
A6	de Oliveira Silva et al. (2018)	Unclear	Unclear	Low	Unclear	Low	Low
A7	Liao et al. (2017)	Low	Low	Low	Low	Low	Low
A8	Huang et al. (2017)	Low	Low	Low	High	Low	Low
A9	Maltais et al. (2016)	Low	Low	Low	Low	Low	Low
A10	Park et al. (2017)	Low	Low	Low	Unclear	Low	Low
A11	Kim et al. (2016)	Low	Low	Low	High	Low	Low